Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
- 24 September 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (4) , 1715-1730
Abstract
The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors, as the alternative to monoclonal antibodies are expected to overcome the disadvantage of mAbs which include production difficulties and their long half-life. Recently, progress has been reported on anti-PD-1/PD-L1 small-molecule inhibitors. In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-molecule inhibitors. The structures and the preclinical and clinical studies of several peptide-based small-molecule candidate compounds in clinical trials are discussed. We also illustrate the design strategies underlying reported nonpeptidic small-molecule inhibitors and provide insight into possible future exploration. Development of small-molecule drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2018ZX09301045002)
- Chinese Pharmaceutical Association
- National Natural Science Foundation of China (21472191, 81773559)
- Guangzhou Municipality (201704030099)
- Guangdong Province (2013A022100019, 2016A050502036)
- Yiling Biopharmaceutical Innovation Foundation
This publication has 80 references indexed in Scilit:
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- The Promise and Challenges of CAR-T Gene TherapyJAMA, 2017
- The future of immune checkpoint therapyScience, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASEThe Lancet, 1967